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Cardiovascular disease collectively accounts for a quarter of deaths world-
wide. Genome-wide association studies across a range of cardiovascular
traits and pathologies have highlighted the prevalence of common non-coding
genetic variants within candidate loci. Here, we review genetic, epigenomic
and molecular approaches to investigate the contribution of non-coding regu-
latory elements in cardiovascular biology. We then discuss recent insights on
the emerging role of non-coding variation in predisposition to cardiovascular
disease, with a focus on novelmechanistic examples from functional genomics
studies. Lastly, we consider the clinical significance of these findings at present,
and some of the current challenges facing the field.1. Introduction
Human individuals differ from each other in millions of DNA sequence variants,
some of which contribute to phenotypic differences in physiology and disease
predisposition. Cardiovascular disease (CVD) comprises a range of monogenic
and complex diseases accounting for a quarter of deaths worldwide. The study
of family pedigrees has revealed newmolecular players in monogenic cardiovas-
cular disorders such as familial forms of cardiomyopathy, yet the most prevalent
cardiovascular conditions are complex diseases with a heritable component.
Facilitated by technological advances in sequencing technology, genome-wide
association studies (GWAS) have analysed human genetic variation across indi-
viduals presenting a range of cardiovascular traits and diseases [1–3]. These
comprise physiological parameters of cardiovascular function, such as heart
rate or electrocardiogram measurements, and common pathologies such as
cardiac arrhythmias and coronary artery disease (CAD).
A general finding from cardiovascular GWAS is the high prevalence of
common genetic associations in the non-coding fraction of the human genome.
The majority of human loci associated with cardiovascular traits and diseases
are not in linkage disequilibrium (LD) with coding exons [4], thus a large fraction
of genetic associations must reflect the effect of variation in gene regulation. Here,
wewill review recent evidence from genetic studies into the potential role of non-
coding DNA elements in cardiovascular physiology and disease, with discussion
of mechanistic insights from molecular approaches evaluating the effect of
non-coding genetic variation on gene regulation and cellular phenotypes.2. Genetic association studies in cardiovascular disease
Population genetics in CVD has classically focused on the analysis of familial
pedigrees of suspected monogenic disorders, and for the last decade on associ-
ation studies investigating complex diseases genome-wide. For common traits
and diseases, GWAS are typically conducted on hundreds to thousands of unre-
lated individuals that are genotyped on up to two million single nucleotide
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Figure 1. Summary of genome-wide association signals and proximal genes for major cardiovascular diseases and traits. (a) Total number of associated single
nucleotide polymorphisms (SNPs) for coronary artery disease (CAD), atrial fibrillation (AF), QT interval duration (QT), idiopathic dilated cardiomyopathy (DCM)
and congenital heart disease (CHD). For each disease or trait, top solid-outline boxes correspond to SNPs at genome-wide significance with p-value lower
than 1 × 10−8, and bottom dashed-outline boxes to sub-threshold SNPs ( p-value < 1 × 10−4). The dashed red line denotes the genome-wide significance
threshold. SNPs located in coding regions of the genome are represented as black bars, and with those in non-coding segments in light grey. Numbers on
top of each bar indicate the total number of associated SNPs at a genome-wide level of significance ( p-value < 1 × 10−8), and percentages the non-coding fraction
across all associated SNPs. Data from [5]. (b) Genes proximal to the associated SNPs in (a). ( p-value < 1 × 10−8) are represented as a Venn diagram for CAD, AF and
QT (centre). Numbers indicate gene counts in each region of the plot, including genes associated with two traits/diseases. The boxes linked to each region
summarize example genes proximal to GWAS signals, and the functional categories they belong to.
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2polymorphisms (SNPs) found in the population at high fre-
quency (greater than 5% for minor alleles). Genotyped SNPs
are then used to impute between 10 and 20 million additional
variants including indels, and each of these variants is tested
for association with a trait of interest, providing a global
view of potential candidate disease loci across the whole
genome. Recently, SNP arrays have been complemented byincluding low-frequency (MAF 1–5%) and rare (MAF < 1%)
non-synonymous coding variants. In this section, we discuss
the findings of GWAS across key types of CVD, and their rel-
evance to our understanding of how non-coding regions of
the genome may contribute to disease risk (see also figure 1).
Association signals fromGWAS are commonly reported for
variants showing a p-value lower than 1 × 10−8, which is
royalsocietypublishing.org/journal/rsob
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3widely accepted as a genome-wide significance threshold
(figure 1a, top bars with solid outline). More recently, several
studies have also interrogated association signals at higher
p-values (typically p < 1 × 10−4), under the assumption that
these may also include functionally relevant signals (figure 1a,
bars with dash outline). Sub-threshold variants have been
shown to include those at a false discovery rate lower than
5% [6], and to enrich for tissue-specific epigenetic signals
[7,8]. Nevertheless, it is likely they are overall weaker in their
functional significance when compared to variants at
genome-wide significance, as suggested by their modest con-
tribution to genetic risk scores [6]. For clarity, we focus our
discussion of GWAS findings on reported variants at
genome-wide significance (p < 1 × 10−8), which to date account
for most of those that have been functionally characterized.
2.1. Coronary artery disease and myocardial infarction
CAD due to atherosclerosis and potential myocardial infarc-
tion (MI), after occlusion of a coronary artery due to plaque
rupture, is a major cause of mortality and morbidity. CAD
is a paradigm of complex disease, with an estimated herit-
ability of 50% [9] and multiple risk factors (e.g. high lipid
levels, hypertension, diabetes and inflammation) which in
turn appear to be under genetic control. Given its huge
societal burden, CAD and MI were among the first complex
diseases to be targeted in GWAS.
To date, genetic associations studies have collectively
assessed over 70 000 CAD cases and hundreds of thousands
of controls, revealing over 160 genomic loci associated with
CAD and MI at a genome-wide level of significance (reviewed
in [10]). CAD and MI share a very similar genetic architecture,
with two notable exceptions (the Abo and the Hdca9 loci) [11].
In line with the complex nature of CAD, genetically associated
loci are involved in a range of biological processes, such as lipid
metabolism, vascular tone, inflammation or vascular remodel-
ling [6,12]. However, despite important biological insights
into variants regulating cholesterol metabolism [13,14] and
nitric oxide signalling [15], the precise molecular mechanisms
underlying the majority of associated SNPs with CAD risk
are largely unknown.
The complex genetic association data in CAD also exem-
plifies the importance of co-occurrence of common risk
variants in a given individual, and their potential joint contri-
bution to disease risk. Given the number and population
frequency of genetic variants associated with CAD, an indi-
vidual is expected to carry over a hundred of currently
known risk alleles. In this regard, a recent evaluation of poly-
genic scores [16] estimated 8% of the population being at
more than threefold increased risk for CAD—a prevalence
20 times higher than the carrier frequency of rare monogenic
mutations conferring a comparable disease risk [17].
2.2. Congenital heart disease
Congenital heart disease (CHD) is the most common type of
birth defect (affecting approx. 1% of live births) and com-
prises structural abnormalities affecting the heart septum,
valves and the outflow tract. CHD is genetically hetero-
geneous, and even within the same abnormality, differences
in clinical symptoms across patients are very common [18].
The post-natal survival of CHD patients has dramatically
improved in the last decade due to the implementation ofcorrective cardiac surgery. However, most CHD patients
suffer cardiac complications in adulthood, with arrhythmias
and heart failure being the most common.
Some forms of CHD are associated with well-known chro-
mosomal abnormalities (such as trisomy of chromosome 21
[19]) and copy number variations, which account for approxi-
mately 25% of cases [20]. Studies to date have identified over
50 genes with point mutations associated with familial CHD,
which largely correspond to cardiac developmental genes (e.g.
transcription factors GATA4 and NKX2–5). However, for the
vast majority of CHD patients, no apparent chromosomal
abnormality or causal mutation can be identified. In fact, famil-
ial studies have often failed to identifya single candidate genetic
variant that completely segregates with the disease [21,22].
These findings collectively suggested a significant contribution
of de novomutations and polygenic inheritance in CHD.
Because congenital defects are expected to be under strong
selective pressure, de novomutations may account for a signifi-
cant fraction of sporadic CHD occurrences. Recent studies
analysing hundreds of disease cases and controls have shown
an increased burden of de novomutations in genes involved in
transcriptional regulation, including enzymes controlling the
reading and removal of histone 3 lysine 4 methylation [23,24]
and the pleiotropic transcription factor NR2F2 [25]. De novo
mutations may account for up to 10% of CHD cases [26],
with an increased prevalence among patients where CHD is
accompanied by extra-cardiac abnormalities such as neurode-
velopmental disorders [24]. More recently, exome sequencing
of approximately 2500 trios suggested distinct gene pathways
associated with de novo and recessive forms of CHD, with
mutations in chromatin-modifying genes being enriched in
de novo sporadic cases [27].
The potential role of polygenic inheritance in CHD has
been highlighted by recent GWAS studies focused on
common genetic variation, which to date have identified a rela-
tively low number of associations at a genome-wide level of
significance (figure 1a). Two strong associations were ident-
ified in tetralogy of Fallot patients, one of which falls in a
large intronic region with potential regulatory function [28].
Across thousands of CHD cases encompassing all major clini-
cal types, genetic associations were most significant when
patients were segregated by CHD subtype, and the strongest
association was found in an intergenic region proximal to the
homeobox transcription factorMSX1 [29].
These studies, therefore, suggest a key role for gene regulat-
ory processes in mediating congenital heart disease. Focusing
on regulatory regions of the developmental transcription
factor TBX5, Smemo et al. [30] were among the first to pro-
vide molecular and mechanistic evidence for the role of
transcriptional enhancers in CHD—more recent examples
will be the focus of later sections of this review.2.3. Long QT syndrome
The continuous and coordinated contraction of the heart relies
on tightly regulated opening and closing of specialized ion
channels in heart muscle cells. Cardiac arrhythmias result
from disruptions in myocyte electrical function and are a lead-
ing cause of sudden cardiac death, stroke and heart failure. The
genetics of a wide spectrum of cardiac rhythm disorders has
been reviewed elsewhere [31]—here, we will focus on two
common arrhythmias, namely long QT syndrome (LQTS)
royalsocietypublishing.org/journal/rsob
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4and atrial fibrillation (AF), which have been the focus of recent
genetic studies.
Cardiac arrhythmias have been classically studied within
family pedigrees, such as in the pioneering work that led to
the mapping of the chromosomal loci underlying hereditary
LQTS [32]. This form of inherited arrhythmia leads to a pro-
longed duration of ventricular action potentials, and thus an
extended QT interval on the electrocardiogram. Affected indi-
viduals have a propensity to a particular form of ventricular
tachycardia known as torsade-de-pointes, and this candegener-
ate into ventricular fibrillation leading to sudden death if
untreated. Familial studies identified three major causative
genes in two potassium and the cardiac sodium channel
genes, which gave rise to the classification of patients into
three main LQTS types. Later work extended the number of
genes linked to hereditary LQTS to 15, although most of these
additional mutations are very rare (reviewed in [33]). In most
cases, LQTS mutations lead to defective channel function or
trafficking, as shown in a number of experimental systems—
including engineered mouse models [34] and human
patient-derived induced pluripotent stem cells (iPSCs) [35].
The QT interval is heritable in the wider population and
GWAS have identified common genetic variants associated
with this electrocardiographic trait. The first study [36] ident-
ified a strong association signal in the NOS1AP locus, a
potential regulator of ion channel function [37]. Subsequent
studies have identified genetic variants associatedwith electro-
cardiographic traits [38,39]. These are proximal to many of the
same ion channel genes that harbour familial LQTS mutations,
in addition to some developmental transcription factors (e.g.
MEIS1 and TBX5) [40]. A recent GWAS of QT interval duration
across over 70 000 individuals identified loci associated with
cardiomyocyte calcium handling, highlighting a potential
role of repolarization pathways in LQTS susceptibility [41]
(see also figure 1).
The variable clinical manifestations in LQTS patients with
the same gene mutations [42] have led to the investigation of
potential modifier genes contributing to incomplete penetrance
or variable expressivity (reviewed in [43])—including non-
coding genetic variants). An elegant study focusing on a
South African founder population for the KCNQ1-A341 V
mutation [44] demonstrated that two common non-coding
NOS1AP variants associatedwith increased riskof life-threaten-
ing arrhythmia in LQTS patients. In fact, variants in this locus
have also been linked to drug-induced LQTS risk [45]. Conver-
sely, a case-control study in LQTS duos identified an intronic
KCNQ1 variant associated with lower arrhythmic risk [46].
Recently, iPSCs were generated from several members of a
familywith type 2 LQTS, including severelyandmildlyaffected
individuals [47]. By combining exome sequencing and electro-
physiological measurements, the authors revealed a protective
gain-of-function mutation in KCNK17 and an aggravating
variant in REM2. In sum, these studies have provided proof-
of-principle evidence for the existence of predisposing and
protective modifier genes in LQTS. Recent prospective analyses
assessing the value of multi-locus genetic scores [48] illustrate
the potential for variants involved in disease predisposition to
inform clinical management of LQTS patients.
2.4. Atrial fibrillation
AF is the most common cardiac arrhythmia (affecting up to 2%
of the general population). It occurs due to abnormal electricalimpulses firing in the atria that override the natural pacemaker
of the heart, and lead to an uncontrolled and highly irregular
heart rhythm. AlthoughAF can develop secondarily to chronic
cardiac stress and other heart diseases, it has a substantial gen-
etic heritability estimated at approximately 60% [49]. Initial
investigations into the genetic causes of AF focused on candi-
date gene screening in cohorts of early-onset lone AF patients
or families showing Mendelian disease segregation. Although
these classical studies discovered a number of rare coding
variants in ion channel genes responsible for generating the
atrial action potential [50], recent population-based approaches
suggest coding mutations account for a relatively small
proportion of genetically determined AF [51].
By contrast, analyses of common and rare variation across
AF patients and controls suggest an important role for non-
coding genetic variants in mediating disease susceptibility.
The first major AF GWAS identified a significantly associated
locus in an intergenic non-coding region on chromosome
4q25, adjacent to the PITX2 gene [52]. The AFGen Consortium
[53] and subsequentmeta-analyses [54,55] have extended these
GWAS to hundreds of thousands of AF patients and controls.
To date, these efforts have collectively identified over 100 geno-
mic regions associatedwithAF, themajority ofwhich liewithin
introns or intergenic regions.
Genetic loci associated with AF are often within the non-
coding regions of ion channel genes such as KCNQ1. These
variants may predispose to AF by shortening or lengthening
atrial action potential leading to changes in atrial tissue refrac-
toriness, and can be carried in multiple combinations of rare
and common variants with epistatic effects [56]. The second
set of associated GWAS loci are proximal to transcription
factors such as PITX2, ZFHX3, GATA4, NKX2–5 and TBX5—
mostly with previously known roles in heart development.
Four AF-associated regions at 4q25 are closely associated
with the PITX2 gene, and thus deficiency of the major heart
isoform PITX2c was thought to mechanistically contribute to
AF. In agreement, haploinsufficient PITX2 mice show a pro-
pensity to atrial arrhythmias and AF [57], albeit coding
mutations in PITX2 are uncommon in AF patients [58]. The
role of non-coding SNPs corresponding to the four association
signals in the 4q25 locus is still under investigation, and
recent studies have demonstrated the interaction of enhancer
elements in this regionwith PITX2, with significant differences
in PITX2c expression levels between allele variants [59].
Intriguingly, evaluation of PITX2c expression in human AF
patients and controls have been inconclusive in observing
significant differences [60], suggesting the effects of PITX2 on
AF susceptibility may occur during development or in
response to cardiac stress in the adult. In this regard, PITX2
is known to interact with other transcription factors whose
loci also harbour AF-associated non-coding variants (e.g.
ZFHX3 and TBX5)—suggesting an altered atrial regulatory
network may play a role in AF pathogenesis (reviewed in
[61]). Thirdly, GWAS loci associated with AF are also found
close to structural heart muscle genes, such as those encoding
for sarcomeric MYH6/7, TTN and associated regulatory pro-
teins (e.g. CAMK2D). Variants in these loci potentially
contribute to an atrial cardiomyopathy that may be exacer-
bated by chronic cardiac stress. In this regard, MYH7
expression has been shown to be elevated in human patients
and animal models of chronic AF [62].
Despite the plethora of genetic associations in AF patients
(figure 1), genetic testing is not recommended in standard
royalsocietypublishing.org/journal/rsob
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5clinical diagnosis. The complexity of GWAS associated genes
in AF and a limited knowledge on the causative role of most
candidate genes probably underlie the poor performance of
polygenic scores based on GWAS [63].
In sum, genetic studies suggest a role for transcriptional
enhancers and non-coding genetic variation in contributing
to disease penetrance in LQTSs, as well as for regulatory net-
works of cardiac development in mediating onset and
progression of AF. Mechanistic examples of specific loci will
be discussed in §4 of this review.
2.5. Cardiomyopathies
Cardiomyopathies are a heterogeneous group of diseases
characterized by impairment of heart muscle function.
Although they can be secondary to factors such as ischaemia
or hypertension, cardiomyopathies are often heritable.
Although left ventricular hypertrophyand systolic heart failure
often associate with cardiomyopathies, we will not cover
either here due to their very diverse aetiologies [64]. Instead,
herewe focus on the twomajor clinical types of primary cardio-
myopathies: hypertrophic cardiomyopathy (HCM) and dilated
cardiomyopathy (DCM). HCM is a major cause of sudden
death and heart failure, and functionally defined by a
characteristic pattern of ventricular hypertrophy and diastolic
dysfunction; whereas DCMmanifests with ventricular dilation
and systolic dysfunction.
More than half of HCMpatients have a family history of the
disease, with a 20–35% figure in DCM. Therefore, genetic
studies have classically focused on linkage analysis and candi-
date gene approaches, revealing rare variants associated with
familial cardiomyopathy. HCM is mainly linked to mutations
in genes for sarcomeric proteins, especially MYH7 [65,66].
Linkage analysis in HCM families not linked to the MYH7
locus has identified mutations in additional genes encoding
contractile elements of the sarcomere, such as MYCBP3 or
TTN2. Further sequencing of candidate loci found HCM-
associated mutations in genes for other components of the
contractile machinery, including MYL2, MYL3 and TNNC1.
Overall, contractile element mutations are found in nearly
half of patients with familial HCM, leading to the notion that
this cardiomyopathy is primarily a disease of the cardiac
sarcomere [67].
By contrast, DCM patients display substantial genetic het-
erogeneity. More than 50 genes have been linked to familial
DCM, some of which overlap with those associated with
HCM. A major DCM-associated gene is TTN, encoding for
the giant protein Titin—mutations in TTN are associated
with 20% of DCM cases [68]. However, current genetic testing
of DCM patients, even with large panels of genes, has only
approximately 50% sensitivity in detecting mutations. Even
within the same family, there is substantial heterogeneity of
symptoms for individuals carrying the same rare variant.
Moreover, the frequency of known pathogenic mutations in
HCMandDCM ismuch lower than the prevalence of these dis-
eases, suggesting up to 3–5% of the population carries genetic
variants associatedwith cardiomyopathy (i.e. a significant frac-
tion of patients have no characterized pathogenic variants).
In linewith these findings, recent large-scale exome sequencing
of DCM patients suggested a robust disease association for
only 12 of 56 genes commonly implicated in DCM [69].
GWAS studies of cardiomyopathy patients have detected
few associated non-coding variants at a high level ofsignificance (figure 1a). GWAS of DCM [70,71] identified a
number of susceptibility loci, corresponding to non-coding
variants proximal to HLA-C and HSP7, and common
coding variants in the BAG3 gene, for which rare variants
were also found in familial DCM [72]. More recent studies
in specific populations have reported non-coding associated
variants in the CACNB4 cardiac channel locus [73] (in an
African American population), and rare coding variants in
the developmental cardiac TF NKX2–5 and the cytoskeletal
protein FLNC in Icelanders [74]. Overall, the low number of
associated loci identified may be related to idiopathic DCM
often being a consequence of pre-existing conditions (such
as congenital heart disease). It is therefore possible that gen-
etic heterogeneity of DCM GWAS cohorts is substantially
higher than that of other CVD GWAS, as suggested by the
low replicability of association signals across studies.
The above results also contrast with reports quantifying the
degree of gene expression changes in DCM patients, which
have documented over 250 genes as differentially expressed
[75]. Among these were many DCM-associated genes in
GWAS, including the cardiac transcription factor TBX20 [76]
and many of its target genes. Focusing on a carefully pheno-
typed cohort, a recent study has also revealed structural
genetic variants (e.g. insertions, deletions and duplications)
associated with DCM [77], most of which reside in non-
coding regions. Nevertheless, the mechanistic role of the few
non-coding genetic variants associated with cardiomyopathies
remains poorly understood.3. Experimental approaches for functional
annotation of non-coding variation
By design, the GWAS studies discussed above identify broad
genomic regions (loci) associated with CVD, which are often
proximal to several candidate genes. This is because common
genetic variants in the human genome are pervasive (occurring
on average every 300 bp) and typically co-segregate in blocks
of genomic DNA. This co-segregation of alleles is termed LD,
and is often the case that GWAS lead variants will be in high
LD (r2 > 0.8) with many other sequence variants within a
locus. Moreover, comprehensive catalogues of common
sequence variation such as the 1000 Genomes Project allow
consideration of all candidate variants. These factors compli-
cate the identification of the individual variant(s) underlying
a GWAS association signal, and have prompted the develop-
ment of statistical methods to identify credible subsets more
likely to contain causal variants (reviewed in [78]).
In parallel, functional interpretation of GWAS results has
prompted detailed and careful annotation of association inter-
vals, spanning variants in high LDwith a lead variant and sub-
threshold genomic variants. In this section, we will review
some of the current experimental approaches aimed at the
functional annotation of GWAS variants and associated loci,
with a focus on epigenomic approaches and the complemen-
tary evidence they provide for an investigation of non-coding
regions associated with CVD. There are two related areas we
will not cover here. First, in vivo transgenic reporter assays pro-
vide rich information on the tissue and developmental
specificity of candidate regulatory elements, and are often
used in combination with the strategies we discuss [79].
Second, we will not discuss gene expression annotation of
GWAS in detail, such as the use of expression quantitative
royalsocietypublishing.org/journal/rsob
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6trait loci (eQTLs) for variant interpretation. A substantial frac-
tion of non-coding GWAS signals corresponds to eQTLs, and
their use for the annotation of cardiovascular GWAS has
been reviewed elsewhere [80].
3.1. Epigenetic annotation of non-coding elements
When combined with specific experimental protocols, sequen-
cing technologies enable genome-wide profiling of hallmarks
of regulatory activity across the genome. Transcription factor
binding can be assessed genome-wide to identify all genomic
elements bound by a protein in a tissue or cell line of interest,
using chromatin immunoprecipitation coupled to DNA
sequencing (ChIP-seq). This strategy can also be applied to his-
tone modifications to identify DNA regions harbouring
epigenetic marks characteristic of active or inactive regulatory
elements. By leveraging these approaches, international con-
sortia such as the ENCODE and Roadmap Epigenomics have
discovered the unexpectedly high proportion of human non-
coding DNA containing biochemical signatures of regulatory
activity [81]. These efforts have profiled the binding of over a
hundred transcription factors in human cells and tissues, as
well as enrichment of histone modifications associated with
the regulatory activity (e.g. promoters and enhancers). Their
results suggest over 35% of the human genome can be con-
sidered as functional based on its potential to regulate tissue-
specific expression patterns. Moreover, similar genome-wide
approaches to profile RNA transcripts have indicated the
human genome is also pervasively transcribed [81].
These genome-wide profiles provide invaluable infor-
mation to interrogate genomic regions from GWAS, for
example, to examine whether associated variants localize
within regions with regulatory activity in a disease-relevant
tissue. In fact, a recent epigenomic analysis of over a hundred
human samples encompassingmajor tissue types [82] has high-
lighted the tissue-specific nature of a good fraction of genetic
association signals. Non-coding GWAS signals were strongly
enriched among genomic elements harbouring marks of regu-
latory activity, most notably H3K4me1 and H3K27ac (both
characteristic of enhancer elements). This enrichment was
markedly tissue-specific: across CVDs and traits, GWAS signals
were most enriched in heart, vasculature and liver epigenomes.
These results highlight the importance of investigating GWAS
genomic regions in relevant tissues and cellular models, and
in the context of dynamic regulatory environments [83]. Of
note, recent work from the mouse ENCODE consortium
reported significant conservation of human andmouse regulat-
ory landscapes [84], supporting the utility of comparing human
and mouse epigenome annotations.
In this regard, recent work has begun dissecting genome-
wide changes in epigenetic marks, transcription factor binding
and chromatin accessibility during cardiac development and in
response to stress (reviewed in [85]). Applying functional geno-
mics to null mouse models for the cardiogenic transcription
factors NKX2–5 and TBX5, Luna-Zurita et al. [86] documented
extensive cooperativity between these transcription factors and
GATA4, which could often be explained by specific binding
motif arrangements. Moreover, genetic ablation of either
factor alone or in double knock-outs showed interdependent
binding between the three factors, including significant ectopic
binding of the remaining twoTFs upon ablation of either one—
suggesting mutations in these factors found in CHD patients
can act both by loss of TF binding and abnormal ectopicbinding of cooperating TFs. Using a similar approach in an
inducible TBX3 transgenic mouse, van den Boogard et al. [87]
mapped genome-wide binding of the transcription factors
TBX3, NKX2–5 and GATA4 in the developing heart, also doc-
umenting significant co-binding by the three TFs. Comparing
gene expression changes upon TBX3 induction with regions
bound by TBX3, the authors defined a core-set of ten ion chan-
nel genes as TBX3 targets, including the SCN5A cardiac
sodium channel locus. Using their TBX3 ChIP-seq data, the
authors identified candidate TBX3-bound enhancers in this
locus and evaluated the heart-specific activity of orthologous
human sequences in a mouse reporter assay. One of the
functionally conserved human enhancers contained a SNP
associated with cardiac arrhythmias, directly overlapping a
TBX3 ChIP-seq peak and corresponding to a highly conserved
position in the T-box binding consensus sequence. Accord-
ingly, a reporter construct with the minor SNP allele did not
respond to TBX3 overexpression, and associated with reduced
activity by 60% in a zebrafish reporter assay. These two reports
exemplify the power of epigenetic annotation approaches to
inform transcriptional mechanisms in CVD, and the function
of disease-associated non-coding variants (see also figure 2a).
Cardiac stressors such as mechanical overload play a well-
documented role in heart disease. Under pressure overload,
the heart has to contract and eject blood against excessive
pressure, for example, caused by systemic hypertension or
aortic stenosis. Over time, this formof stress results in pathologi-
cal hypertrophy of the heart muscle, a process in which
transcription factors active in the fetal heart are thought to be
re-activated [90]. Several recent studies have employed func-
tional genomics approaches to assess how extensive a ‘fetal
gene programme’ is in cardiac hypertrophy. He et al. [91]
focused on transgenic and knock-out GATA4 mouse models to
investigate this cardiac TF in mouse fetal and adult hearts,
and in response to pressure overload. Their results showed
GATA4 binding differed markedly between fetal and adult
samples: while two-thirds of adult GATA4-bound regions
were also bound in E12.5 mouse hearts, 80% of fetal GATA4
peaks were not bound in the adult. Comparison with
H3K27ac data and genes regulated downstreamofGATA4 indi-
cated an important functional role for regions showing both
GATA4 binding and H3K27ac signal, suggesting binding of
this transcription factor mediates H3K27ac deposition and sub-
sequent transcriptional changes. Upon pressure overload in
adult mice, upregulated genes were significantly associated
with fetal-specific GATA4-bound regions. However, cardiac
stress-induced GATA4 binding across a much larger set of
new, stress-specific genomic regions. An earlier study [92] also
found widespread changes in gene expression and the level of
activating (e.g. H3K27ac) and repressive histone modifications
under pressure overload. More recently, histone modifications
associated with active transcriptional enhancers and down-
stream gene expression were profiled in left ventricle tissue
from18 idiopathicDCMpatients andhealthy controls [93]. Ana-
lyses of these data found over 7000 disease-associated regions
showing gains or losses of regulatory activity. By comparison
with data from the human fetal heart, the authors found
around half of the disease-associated regions shifted towards a
fetal-like epigenome and transcriptome. While consistent with
the reactivation of fetal enhancers under cardiac stress and dis-
ease, these results also suggest a significant activation of new
stress-responsive enhancers—which are not active during car-
diac development but may also contribute to heart disease [94].
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Figure 2. Experimental approaches for functional investigation of non-coding elements associated with cardiovascular disease. (a) Epigenomic annotation of the SCN5A/
SCN10A cardiac disease locus in human and mouse left ventricle. Human genome tracks show epigenome signals for three histone marks associated with regulatory activity
(H3K4me3 in blue; H3K27ac in orange and H3K4me1 in green) [82]; GWAS lead SNPs in this locus (black bars); and putative promoters ( purple) and enhancers (orange).
Mouse genome tracks below show ChIP-seq data for cardiac transcription factors GATA4 (blue), NKX2–5 (green) and TBX3 (purple) [88]. Orthologous promoters and
enhancers in the human and mouse loci are connected by light purple and orange guides, respectively. (b) Epigenomic annotation of the KCNH2 QT interval locus
in the human left ventricle (epigenome signals as in (a)). Bottom tracks show genetic variants associated with QT interval duration (black bars), and long range interactions
between the KCNH2 promoter (blue) and enhancer elements (red) [89]. (c) Genomic location of the lead genetic variant rs2595104, associated with atrial fibrillation (AF)
and located upstream of the PITX2c transcript annotation. The grey inset shows the sequence context of the variant, the minor risk allele (0.31 frequency), the major
protective allele (0.69 frequency) and the p-value of the AF association. The regulatory effect of this variant on PITX2c expression was analysed in iPSC-derived cardi-
omyocytes by CRISPR/Cas9 deletion of a 100 bp sequence encompassing rs2595104 (left barplot, 54% reduction); and also by CRISPR genetic editing producing isogenic
cardiomyocytes carrying the major non-risk allele and the minor risk allele (right barplot, 27% difference). Adapted with permission from [59].
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73.2. Long-range chromatin interactions
A key property of non-coding regulatory elements such as tran-
scriptional enhancers is long-rangegene regulation: target genes
of regulatory elements can be located hundreds of kilobasesaway in the linear DNA sequence, complicating efforts to
assign effector genes of disease-associated genetic variants
located in the non-coding genome. However, a range of exper-
imental approaches can be used to detect interactions between
transcriptional enhancers and the promoter regions of distant
royalsocietypublishing.org/journal/rsob
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8genes—therebyaddressing an important limitationof the epige-
netic annotation methods discussed above. The most common
of these techniques are in situ fluorescent hybridization (FISH)
or experiments based onproximity ligation of cross-linked chro-
matin fragments (knownas chromosome conformationcapture)
[95]. Although both techniques have specific advantages
and disadvantages, FISH is intrinsically a low-throughput
approach, and typically favoured to studyspecific loci and inter-
actions, and to independently validate findings from proximity
ligation methods (see [96] for a detailed discussion).
We focus below on chromosome conformation capture
approaches, and their application in the cardiovascular area.
A critical aspect in designing these experiments for the study
of gene regulation is tissue-specificity, both for three-
dimensional chromatin interactions and (especially) the activity
of interacting regulatory elements. This factor underlies the
importance of assaying the right cell type and developmental
stage for meaningful analyses, as exemplified in the studies
discussed in this section.
Some of the key genetic loci associated with cardiac disease
have been analysed with chromosome conformation capture
approaches. Natriuretic peptide A and B (encoded by the neigh-
bouringNPPA andNPPB genes) become expressed in the atrial
and ventricular myocardium during development, and are
strongly induced in the ventricles upon cardiac stress and
heart failure. Because of their paradigmatic roles in heart
development and disease, their regulatory landscapes and
three-dimensional organization were analysed with an adap-
tation of chromatin conformation capture (4C-seq) [97]—in
which locus-specific interrogation of promoter–enhancer
interactions is achieved by sequencing all DNA fragments inter-
actingwith achosengenomic region. By choosingviewpoints on
each side of the NPPA/NPPB locus, the authors showed three-
dimensional interaction profiles that were largely maintained
in the adult and fetal heart, as well as under cardiac stress
induced bypressure overload. These interactionswere even pre-
sent in the liver, a tissue where the two genes are not expressed,
suggesting the three-dimensional conformation of the locus is
permissive, yet leads to gene expression specifically in the
heart. Employing an elegant combination of the 4C-seq
approach, H3K27ac ChIP-seq profiles and transgenic reporter
assays, the study also found adult and fetal enhancers were lar-
gely distinct, with developmental enhancers being locatedmore
distally. However, and in line with results discussed in the pre-
vious section [91], stress-responsive enhancers for NPPA/NPPB
were largely distinct from those regulating its developmental
expression—thus pointing to specific regulatory mechanisms
under cardiac stress. Similar locus-specific studies for the
SCN5A and KCNH2 cardiac arrythmia loci have combined
profiling of regulatory landscapes and three-dimensional inter-
actions with experimental perturbations [88,98]—these will be
discussed in the next section (see also figure 2a and b).
More recently, chromatin conformation capture experiments
have been adapted to interrogate three-dimensional DNA inter-
actions across the whole genome, an approach termed Hi-C.
Such chromatin interaction maps are incredibly complex, and
interactions can be selected for specific genomic regions such
as gene promoters. In an impressive study aimed at annotating
non-coding genetic variants associated with CVD, Montefiori
et al. [89] used this promoter–capture adaptation of Hi-C to
map genomic interactions with the promoters of approximately
22 000 human genes. By applying this approach to human-iPSCs and derived cardiomyocytes (iPSC-CMs), this study pro-
vided a detailed comparison of three-dimensional genome
architecture in a chief experimental systemof heartmuscle func-
tion. Their results revealed approximately 400 000 enhancer–
promoter interactions in these cell types, over half of which
were shared between iPSCs and their derived CMs. Leveraging
matched H3K27ac and H3K4me1 data, the authors showed
chromatin interactions specific to either iPSCs or CMs were
enriched in regulatory elements with active epigenetic marks
in the matched cell-type. Moreover, integration of these results
with GWAS SNPs across a wide range of CVDs showed
approximately 20% of LD SNPs located within distal genomic
elements interacting with promoters of their likely target
genes. In fact, more than 90% of SNP-target interactions did
not involve the nearest gene, highlighting the importance of
long-range regulation for functional interpretation of non-
coding genetic variants. Of note, an earlier study employing
an enhancer-centric Hi-C approach on human coronary artery
smooth muscle cells (HCASMCs) [99] reached similar con-
clusions for GWAS variants associated with CAD—89% of
SNP-promoter contacts in HCASMCs skipped at least one
gene, and 64% were mapped to more than a single gene
target. More recently, an integrative analysis of genetic variants
associated with AF has also made use of epigenome, transcrip-
tome and promoter-capture Hi-C data to score and prioritize
genomic loci for functional validation [8].3.3. Perturbation of non-coding regions by genome
and epigenome editing
A classic limitation in functional genomics studies has been the
reliance on correlative evidence to inform genome function. As
such, the above approaches annotate putative regulatory
elements based on their epigenetic annotation (§3.1), and their
long-range interactions across the genome (§3.2). However,
these strategies do not address the impact of candidate promo-
ters and enhancers (and the genetic variants they harbour) in
cellular and organismal functions. Thanks to major develop-
ments in genome-editing technologies in the last decade, it is
now becoming feasible to functionally perturb non-coding
genomic elements. These technologies have been extensively
reviewed recently [100], and here we will focus on illustrative
applications of genome-editing applied to non-coding elements
in the cardiovascular area. A good fraction of such recent work
employs the CRISPR/Cas9 technique, an approach based on
the expression of an RNA-directed and sequence-specific
bacterial nuclease, which can be employed for genetic or epige-
netic editing of specific non-coding elements and genetic
variants. However, classical genetics based on homologous
recombination has also been successfully employed to target
regulatory elements [101].
Recent work by Dickel et al. [102] provided a powerful
example of genetic deletion of candidate genomic elements
associated with CVD. Leveraging a range of epigenetic data-
sets in adult and fetal heart tissue from mouse and humans,
the authors built a compendium of approximately 10 000
genomic elements with evidence of enhancer function in the
heart [102]. By comparing these regions with current catalo-
gues of human genetic variants associated with cardiac traits
and diseases [5], Dickel et al. [102] found approximately 900
variants in high-scoring heart enhancers. In elegant proof-of-
royalsocietypublishing.org/journal/rsob
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9principle experiments, genetic deletion of two predicted
enhancers proximal to the sarcomeric genes MYL2 and
MYH7 led to measurable cardiomyopathy phenotypes in the
mouse, such as cardiomyocyte disarray and reduced cardiac
output. Overall, these experiments provide compelling evi-
dence for the functional impact of GWAS variants in cardiac
disease phenotypes in vivo. More recently, a similar approach
was taken to delete large genomic regions encompassing
non-coding genetic variants associated with AF [8].
In vitro genetic editing in human models represents an
exciting complementary approach to investigate the function
of disease-associated variants and the genomic regions they
occur in. For example, iPSC models of cardiomyocyte function
can be used to interrogate non-coding regions associated with
myocardial pathologies in which marker gene expression sub-
stantially differs between humans and mice [103]. A recent
study focusing on the p.R453C-MYH7 pathogenic mutation
in HCM [104] highlights the usefulness of these models for
detailed characterization of myocardial phenotypes associated
with discrete genetic perturbations. By careful CRISPR/Cas9
engineering of this mutation across three independent iPSC
lines (for wild-type, heterozygous and homozygous mutants),
the authors demonstrate the dose-dependent contribution of
this coding mutation to several hallmarks of HCM, such as
increased cardiomyocyte size, sarcomeric disarray and
arrhythmogenic alterations in calcium handling. This study
illustrates the potential of human in vitromodels for functional
investigation of non-coding disease-associated variants and
the regulatory elements they reside in—recent studies in this
direction are discussed in the next section (see also figure 2c).
CRISPR/Cas9 approaches have also beenadapted tomodify
the epigenome, although their application to cardiovascular loci
has been limited to date. By combining a deadCas9 proteinwith
transcriptional activators or repressors, CRISPR activation and
CRISPR inhibition (CRISPRi) approaches allow targeted pertur-
bation of regulatory elements without direct genetic
modification. A recent high-throughput study used CRISPRi
for functional perturbation of regulatory epigenomes [105].
The study used an elegant approach with CRISPRi of a gene of
interest in conjunctionwith FISH labellingof single cells (accord-
ing to their RNA expression for the targeted gene). By flow-
sorting perturbed cell populations based on the RNA FISH
signal, the method allows the binning of cells according to
their expression level for the gene of interest, which is associated
with abundance of guide RNAs in that bin by high-throughput
sequencing. The authors applied this strategy to the analyses of
over 3000 enhancer-gene connections across 30 genes—includ-
ing complex connections involving enhancers regulating up to
five genes, and individual genes regulated by up to 14 distal
elements. Consistent with the high degree of redundancy and
robustness in mammalian regulatory landscapes, a relatively
small 141 of the tested interactions between regulatory elements
and genes led to significant effects on gene expression, which
were of modest effect size on average (median 22%).4. Mechanistic insights into the role of
non-coding regulatory variation in
cardiovascular disease
This section will focus on selected examples of the appli-
cation of complementary experimental approaches (§3) tothe investigation of genetic regions associated with CVD,
with a focus on non-coding variants and the larger promoter
and enhancer elements they occur in. For completeness, we
summarize selected and additional studies in table 1. Finally,
we discuss the mechanistic insights these studies are starting
to provide on the role of regulatory elements in diseases of
the cardiovascular system.
4.1. Disruption of transcription factor binding sites
Genetic variants associated with CVD have long been postu-
lated to result in altered binding of transcription factors, such
as those directing cardiac development. Pioneering work by
Smemo et al. [30] integrated functional genomics and targeted
sequencing of CHD patients to identify a mutation within an
enhancer element for the TBX5 gene segregating with the
disease. In silico analyses suggested the mutation alters a
binding site for the TAL1 transcription factor, and disrupted
the activity of the enhancer in vitro and in transgenic mouse
and zebrafish models. Similarly, Kapoor et al. [116] carried
out a detailed mapping of GWAS variants associated with
LQTS in the NOS1AP locus, including integration with avail-
able functional genomics data. By interrogating 12 variants in
reporter assays, the authors revealed a genetic variant in an
enhancer element proximal to NOS1AP. This SNP clearly
affected enhancer activity in vitro, although the identity of
the bound protein remains unknown.
More recently, non-coding variants associated with AF in
the PITX2c locus have been analysed using a diverse exper-
imental toolkit [59] (see also figure 2c). This elegant study
focused on variant annotation within the LD block most prox-
imal to PITX2c, out of four showing statistical association in
this locus. Through the integration of genomic data and repor-
ter assays, the authors identified a potentially functional
enhancer variant. Generation of a CRISPR/Cas9 model of the
risk allele in hESC-derived CMs showed a 29% decrease in
enhancer RNAs from this region, suggesting the risk allele dis-
rupts enhancer activity. The authors combined in silico
sequence analysis and in vitro assays to show the risk variant
affects a binding site for the TFAP2A transcription factor
which was confirmed through reduced in vivo binding of this
protein to the risk allele in hESC-CMs. Moreover, downstream
effects on PITX2c expression were analysed upon deletion of
the associated SNP (30–54% reduction), as well as by compar-
ing risk versus non-risk alleles (27% reduction). Lastly, knock-
down experiments using interference RNA demonstrated the
effects of the regulatory variant being dependent on the
expression of TFAP2A and its cofactor CITED2. In a similar
vein, a recent functional genomics approach focusing on the
analysis of CAD variants in HCASMs after perturbation by
pro- or de-differentiation growth factors [109] selected candi-
date genetic variants based on the integration of epigenetic
profiles for chromatin accessibility, enhancer histone marks
and transcription factor binding. The authors focused on a can-
didate intronic variant in the SMAD3 locus predicted to disrupt
a canonical AP1 motif. By combining allele-specific ChIP in
HCASMs from individuals heterozygous for this SNP with
overexpression and knock-down of AP1 members, this study
provided convincing evidence for disruption of AP1 binding
by the minor, protective allele—additionally suggesting
that, compared to other candidate variants, the greater effect
size of this SNP may be due its disruption of an AP1
motif. In sum, these works illustrate the integration of
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12complementary strategies to investigate non-coding genetic
variants, and provide compelling mechanistic evidence for
their role in disrupting the tissue-specific binding of transcrip-
tion factors and downstream gene expression (see also table 1
for additional examples).
4.2. Long-range gene regulation
As discussed in previous sections, a key challenge in function-
ally interrogating non-coding genetic variants associated
with human disease is the ability of regulatory elements to
target genes at very long distances. Although this inherent
property of transcriptional enhancers complicates assigning
non-coding variants to their likely effector genes, several
recent studies provide mechanistic examples for long-range
gene regulation mediated by regulatory elements harbouring
genetic variants associated with specific forms of CVD, or
cardiovascular risk factors such as obesity.
The SCN5A/SCN10A locus is genetically associated with
congenital heart disease and cardiac arrhythmias such as
Brugada syndrome. Van den Boogaard et al. [88] reported the
first detailed analysis of non-coding variants in this cardiac dis-
ease locus, through a combination of functional genomics
approaches and reporter assays. Employing the 4C assay for
targeted interrogation of three-dimensional chromatin inter-
actions (see §3.2), the authors showed that the most likely
functional variant in this locus—which had been ascribed to
the SCN10A gene based on genomic distance—in fact phys-
ically contacted the SCN5A promoter, and was associated
with allele-specific SCN5A expression in humans. In line
with studies discussed in the previous section, the risk allele
was predicted to disrupt a T-box binding motif, as suggested
by in vitro reporter assays. Using a similar approach, a recent
study characterized variants associated with AF in the
PRRX1 locus [119]. Combining interaction frequency data
from published Hi-C studies and locus-specific validation in
cardiac fibroblasts, the authors demonstrated a physical
interaction between an enhancer element harbouring a dis-
ease-associated variant and the PRRX1 promoter. Moreover,
suppression of PRRX1 expression led to shortening of the
atrial action potential in iPSC-derived cardiomyocytes—an
electrophysiological hallmark of AF.
Obesity is a major risk factor for CVD, and the genetic basis
for its heritability has been the focus of several association
studies [124,125]. One of the lead genomic signals associated
with obesity in humans corresponds to intronic variants
within the FTO locus, and follow-up studies have suggested
this gene is implicated in the control of body mass [126].
Smemo et al. [123] employed a series of elegant experiments
to revisit the molecular genetics of this locus. Using 4C-seq to
map genomic interactions between the FTO intronic region
and surrounding promoters, they showed a lack of interaction
with the FTO promoter in the adult mouse brain. Instead, the
authors detected robust interactions between the obesity-
associated interval and the IRX3 gene (located half a megabase
downstream). Moreover, obesity-associated SNPs correlated
with IRX3 expression in the human brain, but not with that
of FTO—suggesting that the association signal overlaps an
enhancer element involved in long-range regulation of IRX3
in the brain. To support this conclusion, the authors performed
detailed phenotyping of mice deficient for IRX3, which sup-
port a global and hypothalamus-specific role for this gene in
control of body mass. Although these results are also
royalsoc
13compatible with the proposed role of FTO in modulating obes-
ity, they powerfully highlight the importance of long-range
gene regulation as a mechanismmediating the effect of genetic
variants associated with CVD.ietypublishing.org/journal/rsob
Open
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A key finding from genomic consortia such as the ENCODE
project [81] has been the pervasive transcription of the
human genome. Current estimates suggest that up to 80% of
our genomemay be actively transcribed, including a large var-
iety of non-coding RNA species such as microRNAs, enhancer
RNAs and long non-coding RNAs (lncRNAs). In this section,
we focus on the emerging roles of lncRNAs in cardiovascular
biology (reviewed in [127]), and on recent examples of CVD-
associated genetic variants that have been mechanistically
linked to lncRNAs.
The potential relevance of lncRNAs on cardiac develop-
ment was highlighted by the discovery of FENDRR, a
lncRNA highly expressed in the posterior mesoderm, and
whose genetic deletion leads to impaired heart development
[128]. Recent work has also implicated lncRNAs in the gene
expression response to cardiac stress [129,130]. Focusing on
the transcriptional response to pressure overload in mice,
Wang et al. [131] recently reported and functionally character-
ized the cardiomyocyte-specific lncRNACHAER1. Employing
knock-out mice and perturbation experiments in vitro, the
authors proposed this lncRNA is necessary and sufficient
for cardiomyocyte hypertrophy, which suggested its role in
regulating gene expression under cardiac stress. Functional
genomics experiments in normal and CHAER1-deficient
cardiomyocytes indicated negative regulation of H3K27
methylation by CHAER1, and further in vitro work showed
this effect may be mechanistically due to interaction between
CHAER1 and the chromatin repressive protein PRC2—which
appears to be transiently enhanced early in response to hyper-
trophic signals, and precedes a decrease in H3K27me3 and
induction of hypertrophic gene expression.
One of the first indications of a putative role of lncRNAs
in heart disease came from genetic studies identifying a sus-
ceptibility locus for MI [132], encoding a lncRNA termed MI
associated transcript (MIAT). However, transcriptomic
studies of mouse brain development suggest MIAT may
have pleiotropic effects on gene expression, including on car-
diovascular-relevant pathways such as WNT signalling [133].
In addition, this lncRNA has also been linked to fibrosis in
HCM and disease prognosis [134]. More recently, detailed
experimental annotation of the KNCH2 locus (associated
with QT interval duration in humans) identified regulatory
elements in the mouse controlling expression of its two iso-
forms KCNH2A and B, one of which controls a lncRNA
likely involved in KCNH2 regulation [98]. Lastly, genetic
association studies of CAD independently identified the
9p21 susceptibility locus, which is adjacent to the lncRNA
CDKN2B-AS1 (also known as ANRIL), and hundreds of kilo-
bases from the protein-coding genes CDKN2A and CDKN2B.
Although the biological function of ANRIL and the nearby
disease-associated variants is incompletely understood,
recent studies have provided evidence for its role in CVD
[101,106,107,112]—mechanistic insights into such complex
genetic loci will be the focus of the next section.4.4. Mechanistic insights on complex genetic loci
The variety of genetic, epigenomic and molecular approaches
currently available for the study of non-coding genetic var-
iants is beginning to allow very detailed investigation of
complex genetic loci, such as those harbouring multiple sus-
ceptibility variants, or associated with diverse cardiovascular
phenotypes. In this section, we discuss two recent studies that
exemplify the power of integrative experimental approaches
to provide mechanistic insights into complex disease genetics.
Gupta and colleagues [110] recently conducted a detailed
study of the 6p24 cardiovascular risk locus, overlapping the
PHACTR1 gene and associated with susceptibility to several
CVDs, such as CAD, migraine headache and hypertension.
Using imputation-based fine mapping and probabilistic esti-
mation of causal SNPs in the locus, the authors focused on
a lead variant showing association of its minor allele with
increased risk for CAD, but decreased risk of migraine head-
ache or hypertension—suggesting a role in endothelial
function. The study next employed available epigenomic
datasets to show the likely causal SNP overlaps an enhancer
element with strong H3K27ac signal specifically in aortic
tissue. Using an in vitro system of iPSC-derived endothelial
and vascular smooth muscle cells, the authors conducted ele-
gant gene editing experiments for biallelic deletion of an
approximately 90 bp region containing the enhancer variant,
which led to higher expression of the distal endothelin-1
(EDN1) gene. These results were combined with similar
experiments comparing iPSC clones edited to harbour homo-
zygous major (A/A) and homozygous minor (G/G) versions
of the lead SNP. Gene expression profiling of these clones
showed over 200 differentially expressed genes, which
included known regulators of vascular function (e.g.
COL4A1 or FN1). Among differentially expressed genes,
EDN1 was the closest to the lead variant, with the minor
allele driving an approximately 20% increase in EDN1
expression. Although clearly consistent with the enhancer
variant acting through the regulation of EDN1, chromatin-
conformation capture experiments failed to show a robust
interaction between this variant and the EDN1 promoter.
Based on these observations, the authors proposed amodel
where the differing associations of the 6p24 locus with risk for
CVDs can be explained by context-dependent effects of EDN1
on the vasculature. First, increased endothelial production of
EDN1 (associated with the risk allele) and binding to the ETA
receptor can promote atherosclerosis. Second, increased
EDN1 binding to the same receptor in VSMCs leads to vaso-
constriction (and reduced susceptibility to migraine). Lastly,
the association of the minor allele with lower systolic blood
pressure may be due to EDN1 binding to the ETB receptor in
the endothelial cells of large systemic arteries, leading to sys-
temic vasodilation. Overall, these results show the potential
of integrating genetic, epigenetic and gene editing approaches
for functional investigation of risk variants associated with
multiple diseases and phenotypes.
In a similar vein, a recent study focused on the analysis of
the 9p21.3 CVD locus [112] (§4.3), an approximately 60 kb
region associated with CAD risk, and containing over a hun-
dred genetic variants [11] that commonly occur in one of two
haplotypes (‘risk’ and ‘non-risk’). The authors used an elegant
set of experiments to functionally analyse the aggregate effect
of variants in each haplotype. First, the authors compared
previously generated iPSCs homozygous for the non-risk
royalsocietypublishing.org/journal/rsob
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14(NN) and risk haplotypes (RR) with homozygous deletion
clones of either haplotype. Although these deletions did not
seem to impact iPSC function, differentiation of edited
clones towards VSMCs showed faster proliferation of meso-
derm precursors in RR cells. Deletion of the risk haplotype
reverted proliferation rates to those of NN mesodermal
progenitors, and resulted in differential expression of over a
hundred genes. In fully differentiated VSMCs this effect was
amplified, with deletion of the risk haplotype associating
with thousands of differentially expressed genes. Deletion of
the risk haplotype also seemed to restore VSMCs to a gene
expression pattern resembling that of the non-risk haplotype,
and accordingly measures of VSMC function (such as contrac-
tile force) were reduced in cells harbouring the risk haplotype,
and restored to non-risk levels upon deletion of the 60 kb
region.
To inform the mechanistic basis of the gene expression and
functional changes associated with the risk haplotype, the
authors focused on the complex splicing of the CDKN2B-AS1
lncRNA (the terminal exons of which are contained in the risk
interval). Short isoforms were specifically detected in VSMCs
harbouring the risk haplotype, and their overexpression in
non-risk VSMCs induced morphological and functional
changes resembling those in RR VSMCs, such as reduced
contractile force. However, gene expression changes upon
expression of short CDKN2B-AS1 isoforms did not recapitulate
most of those associated with the risk haplotype—suggesting
that the functional effects of risk variants in this locus are not
solely mediated by altered expression of CDKN2B-AS1. In
sum, this study provides a powerful example of combining
genetic editing and phenotyping approaches for the detailed
characterization of complex disease-associated haplotypes.5. Clinical significance of cardiovascular
non-coding variants
The results of cardiovascular GWAS studies (§2) have
undoubtedly succeeded in characterizing the genetic archi-
tecture of CVDs—especially for prevalent conditions such
as CAD and AF, for which large numbers of patients and
controls have been analysed. Nevertheless, in terms of clinical
applicability, the ultimate goal is to understand cardiovascular
pathophysiological mechanisms, establish improved risk
predictionmethods and develop effective therapies. Functional
annotation of GWAS findings (§3) and mechanistic studies
of individual loci (§4) have contributed important insights
into pathophysiological pathways, yet many challenges
remain in leveraging cardiovascular non-coding variation for
clinical application.
One area of substantial development is the use of
non-coding GWAS signals in risk prediction. Most CVDs are
polygenic, and perturbation experiments of individual non-
coding variants are consistent with small individual effects
on disease susceptibility—which can be aggregated in genetic
scores predictive of individual disease risk or treatment
response. This strategy has been recently applied to common
polygenic diseases, and suggested polygenic risk scores can
identify individuals at a similar risk than that conferred by
rare monogenic mutations [16]. Because genetic risk scores
can be assessed at birth, they may be particularly useful in
risk prediction among younger patients with a reduced cumu-
lative impact of lifestyle factors [135]. This caveat may explainwhy genetic risk scores only modestly improve the cardiology-
based prognosis for diseases such as AF [63]. Nevertheless,
increased knowledge of the mechanistic significance of
GWAS loci will be key in improving risk prediction from
non-coding cardiovascular variants.
A second challenge is the substantial missing heritability in
current studies. A good example not covered above is blood
pressure GWAS (reviewed in [2]). Familial studies of blood
pressure estimate up to 50% heritability, yet the collective
effect of all GWAS loci only explains approximately 10%.
Significant gene–gene and gene–environment interactions,
structural variation, rare variants and epigenetic mechanisms
likely contribute to this missing heritability. In this regard,
resources such as the UK Biobank [136] are instrumental in
the development of experimental designs and analytical
approaches to systematically evaluate the interaction between
disease genetics and the environment. It is also possible that
substantial missing heritability remains hidden in GWAS
datasets as sub-threshold variants, corresponding to context-
dependent risk effects thatmay bedependent on environmental
influences found in particular stages of the disease.
Lastly, the ultimate challenge of CVD genetics is the devel-
opment of novel treatment strategies based on genetically
supported targets [137]. Although much progress is needed
in mechanistic understanding of non-coding GWAS variants,
these already point to novel therapeutic pathways. First, non-
coding variants influence traditional risk factors, such as
lipid metabolism, that may be treatment targets themselves.
An example is the PCSK9 CAD risk locus. PCSK9 functions
in LDL cholesterol metabolism and several compounds are in
development to inhibit its effect in the circulation. Second,
non-coding GWAS variants are also key in suggesting
disease-driving molecular processes that could be exploited
therapeutically, such as an altered atrial gene regulatory
network in AF. Lastly, non-coding genetic variation can also
be used to develop individualized treatment strategies.
Although the success of genetic testing for patient stratification
has been limited to date, individuals with high genetic risk
scores appear to have distinct therapeutic responses, such as
a larger benefit from statin treatment [138]. Nevertheless, the
clinical application of polygenic risk scores for therapeutic tar-
geting is currently hampered by relatively low precision [139].6. Conclusion and future perspectives
Facilitated by key technological developments in sequencing
technology, genetic editing and integrative analyses, CVD
genetics has made tremendous progress in identifying and
prioritizing human genomic intervals associated with disease
predisposition. Genetic association studies now involve
global efforts to comprehensively characterize putative suscep-
tibility loci. Critically, complementary experimental
approaches allow very detailed epigenetic annotation of dis-
ease-associated loci, and are providing important insights
into the genomic and molecular complexity of gene regulatory
programmes in disease-relevant contexts. Lastly, integrative
strategies leveraging multi-level approaches are beginning to
inform the role of genetic variants and risk haplotypes in
cellular and complex phenotypes.
This progress notwithstanding, a number of key challenges
remain. First, mechanistic insights for the vast majority of loci
associated with CVD are yet to be determined, posing a
royalsocietypublishing.org/journal/rsob
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15daunting task that calls for novel strategies to prioritize loci for
functional testing. Second, many disease-associated regions
harbour complex haplotypes with dozens to hundreds of var-
iants, and determining the contribution of individual SNPs in
complex genetic loci will likely require new experimental
approaches. Third, most CVDs with a genetic component
also occur in the context of multiple environmental factors,
such as metabolic disease and chronic cardiac stress. Untan-
gling the contributions of genetic and environmental cues to
complex CVD constitutes a primary challenge in the field that
are likely to require improved integration of genetic findings
and experimental modelling of environmental risk factors.
A number of emerging approaches andmodels have begun
to address these. Data integration strategies incorporatingmul-
tiple experimental datasets and genetic GWAS findings are
increasingly being used to rank non-coding genetic variants
for functional experiments [8,102]. Further development of in
vitro modelling of subtype-specific CVD [140] will be needed
to fully realize the potential of human ‘disease in a dish’studies. The complex nature of many CVDs is also calling for
improved strategies to evaluate tissue-specific contributions
experimentally, such as the development of engineered
human tissues [141]. Lastly, novel high-throughput approaches
to screen gene expression contributions [105] and tissue-
specificity [142] of regulatory elements (and the non-coding
variants within) should be pivotal in gleaning mechanistic
insights into how gene regulation contributes to onset and
progression of CVDs.Data accessibility. This article has no additional data.
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